Last reviewed · How we verify

NCT06703125: Alama

The Alama Project: Autism Outcomes and Neurobehavioral Markers in Young Children Born to Mothers With HIV in Kenya

Recruiting now NA Last updated 11 April 2025
What this trial tests

NA trial testing Eyelink Portable Duo in Autism in 850 participants. Currently enrolling.

Timeline
11 February 2025
Primary endpoint
28 February 2029
28 February 2029

Quick facts

Lead sponsorIndiana University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment850
Start date11 February 2025
Primary completion28 February 2029
Estimated completion28 February 2029
Sites1 location across Kenya

Drugs / interventions tested

Conditions studied

Sponsor

Indiana University

Who can join

Adults 24 Months to 72 Months, any sex, with Autism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will use a non-invasive remote eye-tracking system (Eyelink Portable Duo) to acquire a short series of eye-tracking measures to determine whether these can predict autism diagnoses in both children exposed to HIV and uninfected (CHEU) and children not exposed to HIV and uninfected (CHUU).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Eyelink Portable Duo

Trials testing the same drug.

Other recruiting trials for Autism

Currently open trials in the same condition.

Other Indiana University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06703125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing